20.57
price up icon2.54%   0.51
after-market 시간 외 거래: 20.11 -0.46 -2.24%
loading
전일 마감가:
$20.06
열려 있는:
$20.025
하루 거래량:
778.15K
Relative Volume:
0.77
시가총액:
$2.55B
수익:
$181.74M
순이익/손실:
$-296.81M
주가수익비율:
-12.03
EPS:
-1.71
순현금흐름:
$-402.70M
1주 성능:
+2.95%
1개월 성능:
+9.30%
6개월 성능:
-15.83%
1년 성능:
-26.93%
1일 변동 폭
Value
$19.63
$20.59
1주일 범위
Value
$19.20
$20.59
52주 변동 폭
Value
$17.05
$39.83

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
명칭
Arrowhead Pharmaceuticals Inc
Name
전화
626-696-4702
Name
주소
177 E COLORADO BLVD, PASADENA, CA
Name
직원
525
Name
트위터
@ArrowheadPharma
Name
다음 수익 날짜
2024-11-27
Name
최신 SEC 제출 서류
Name
ARWR's Discussions on Twitter

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-12-04 개시 BofA Securities Buy
2023-09-19 개시 Citigroup Neutral
2023-07-21 개시 TD Cowen Outperform
2023-05-12 다운그레이드 SVB Securities Outperform → Market Perform
2023-04-26 개시 SMBC Nikko Outperform
2023-04-12 업그레이드 SVB Securities Market Perform → Outperform
2023-03-21 개시 Bernstein Mkt Perform
2022-09-09 개시 Morgan Stanley Equal-Weight
2022-05-11 업그레이드 Robert W. Baird Neutral → Outperform
2022-01-19 재개 Goldman Buy
2021-08-06 재확인 Chardan Capital Markets Buy
2021-06-04 재개 Robert W. Baird Neutral
2021-02-05 재확인 H.C. Wainwright Buy
2020-12-21 다운그레이드 Robert W. Baird Outperform → Neutral
2020-12-16 개시 UBS Buy
2020-11-19 개시 Citigroup Buy
2020-05-13 개시 RBC Capital Mkts Outperform
2020-05-08 업그레이드 Oppenheimer Perform → Outperform
2020-04-15 업그레이드 Cantor Fitzgerald Neutral → Overweight
2020-03-24 업그레이드 SVB Leerink Underperform → Mkt Perform
2020-03-17 개시 Goldman Neutral
2020-01-21 개시 SVB Leerink Underperform
2019-12-13 개시 Oppenheimer Perform
2019-11-29 재확인 Chardan Capital Markets Buy
2019-11-27 재확인 B. Riley FBR Buy
2019-11-25 업그레이드 Robert W. Baird Neutral → Outperform
2019-10-24 다운그레이드 Robert W. Baird Outperform → Neutral
2019-10-22 재확인 Chardan Capital Markets Buy
2019-10-03 개시 Robert W. Baird Outperform
2018-09-07 업그레이드 B. Riley FBR Neutral → Buy
2018-09-06 재확인 Chardan Capital Markets Buy
2018-08-08 재확인 Cantor Fitzgerald Overweight
2018-07-02 재확인 Chardan Capital Markets Buy
모두보기

Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스

pulisher
07:31 AM

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - The Bakersfield Californian

07:31 AM
pulisher
Nov 04, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace

Nov 04, 2024
pulisher
Nov 04, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace

Nov 04, 2024
pulisher
Nov 03, 2024

abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Arrowhead Launches FCS Awareness Campaign - Baystreet.ca

Nov 01, 2024
pulisher
Nov 01, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow

Nov 01, 2024
pulisher
Nov 01, 2024

In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Nov 01, 2024
pulisher
Oct 31, 2024

International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

(ARWR) Long Term Investment Analysis - Stock Traders Daily

Oct 30, 2024
pulisher
Oct 30, 2024

Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat

Oct 28, 2024
pulisher
Oct 21, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat

Oct 21, 2024
pulisher
Oct 20, 2024

(ARWR) Trading Signals - Stock Traders Daily

Oct 20, 2024
pulisher
Oct 18, 2024

Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com

Oct 16, 2024
pulisher
Oct 15, 2024

Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace

Oct 15, 2024
pulisher
Oct 11, 2024

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com

Oct 11, 2024
pulisher
Oct 10, 2024

Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highl - GuruFocus.com

Oct 09, 2024
pulisher
Oct 09, 2024

How to Take Advantage of moves in (ARWR) - Stock Traders Daily

Oct 09, 2024
pulisher
Oct 08, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Overweight Rating at Piper Sandler - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Goldman Sachs holds Neutral rating on Arrowhead stock By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 08, 2024

Arrowhead Pharma maintains Buy rating from TD Cowen after R&D day insights - Investing.com Canada

Oct 08, 2024
pulisher
Oct 08, 2024

Arrowhead Pharma retains Overweight rating from Piper Sandler By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 07, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year LowShould You Sell? - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

ARWR stock touches 52-week low at $18.14 amid market challenges - Investing.com Canada

Oct 07, 2024
pulisher
Oct 07, 2024

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Millennium Management LLC - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Bank of Montreal Can Buys 30,866 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment? - Simply Wall St

Oct 04, 2024
pulisher
Oct 03, 2024

Arrowhead: A First Approval LikelyJury Still Out On Investment Opportunity (ARWR) - Seeking Alpha

Oct 03, 2024
pulisher
Oct 03, 2024

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 03, 2024
pulisher
Oct 01, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low at $18.61 - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Severe Hypertriglyceridemia Market Growth to Accelerate - openPR

Sep 30, 2024
pulisher
Sep 30, 2024

Severe Hypertriglyceridemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, AstraZeneca, Kowa - Barchart

Sep 30, 2024
pulisher
Sep 29, 2024

Squarepoint Ops LLC Invests $9.98 Million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Sep 29, 2024
pulisher
Sep 28, 2024

(ARWR) Investment Analysis and Advice - Stock Traders Daily

Sep 28, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Arrowhead Pharmaceuticals stocksiRNA pioneer targets metabolic diseases - Investing.com Canada

Sep 27, 2024
pulisher
Sep 26, 2024

Arrowhead Pharmaceuticals' (ARWR) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Arrowhead stock touches 52-week low at $19.43 amid market shifts - Investing.com Canada

Sep 25, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Reduces Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Sep 25, 2024
pulisher
Sep 24, 2024

Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand - Clinical Trials Arena

Sep 24, 2024
pulisher
Sep 23, 2024

With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners - Yahoo Finance

Sep 23, 2024
pulisher
Sep 23, 2024

Arrowhead Moving Into Commercial Territory - In Vivo

Sep 23, 2024
pulisher
Sep 23, 2024

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - BioSpace

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Has $231.02 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Sep 23, 2024
pulisher
Sep 21, 2024

Seven Eight Capital LP Sells 40,663 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Sep 21, 2024
pulisher
Sep 17, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 12-Month Low at $20.04 - MarketBeat

Sep 17, 2024

Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Arrowhead Pharmaceuticals Inc 주식 (ARWR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Vakiener Victoria
Director
May 02 '24
Sale
23.31
1,799
41,935
30,205
Hamilton James C
Chief Discovery/Trans Medicine
Apr 01 '24
Sale
28.03
6,000
168,180
204,851
Lu Hongbo
Director
Mar 19 '24
Buy
28.00
1,000
28,000
32,680
Lu Hongbo
Director
Mar 20 '24
Buy
27.50
1,000
27,500
33,680
Lu Hongbo
Director
Mar 18 '24
Buy
27.49
1,000
27,490
31,680
Myszkowski Kenneth Allen
Chief Financial Officer
Mar 06 '24
Sale
35.19
40,000
1,407,600
400,600
Anzalone Christopher Richard
Chief Executive Officer
Jan 31 '24
Option Exercise
14.54
57,499
836,035
3,772,547
Anzalone Christopher Richard
Chief Executive Officer
Jan 31 '24
Sale
32.35
57,499
1,860,019
3,715,048
Hamilton James C
Chief Discovery/Trans Medicine
Jan 12 '24
Sale
36.89
7,940
292,904
210,851
GIVEN DOUGLAS B
Director
Jan 11 '24
Sale
38.06
2,911
110,788
129,711
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):